Methods: Tissues from 150 patients treated as SCLC were stained for multiple molecular markers including Bcl-2 and Mcl-1. Frequency and intensity of expression were measured on a scale of 0-4 (freq 0 ...

Methods: MBZ, TMZ and Bcl-2 anti-sense-induced melanoma growth inhibition were analyzed using MTT assay in SKM-173 and A375 metastatic melanoma cells. Drug interaction was analyzed through ...

At the time of the deal, Fosun hyped up BCL-2 as an “increasingly important therapeutic target in cancer biology.” Lilly presumably agreed, handing over $40 million and pledging up to $400 ...

Lisaftoclax is a proprietary, novel orally administered small-molecule Bcl-2 selective inhibitor developed by Ascentage Pharma to treat patients with malignancies by selectively blocking the ...